Table 1

Characteristics of healthy control subjects and patients with type 2 diabetes participating in the pilot and main studies

Pilot study: glucose-stimulated insulin secretion, effects of exogenous GLP-1 [7-36] amide ± exendin [9-39]Main study: meal-stimulated insulin secretion
and effects of vildagliptin vs. placebo ± exendin [9-39]
CharacteristicHealthy control subjectsHealthy control subjectsPatients with type 2 diabetes
Sex, n
 Female233
 Male42629
 % female33.310.39.4
Age (years)45 ± 1231–5860 ± 941–7261 ± 937–73
BMI (kg/m2)23.5 ± 1.920.7–26.127.1 ± 2.620.7–32.228.7 ± 3.323.1–34.8
Fasting plasma glucose (mmol/L)4.7 ± 0.63.7–5.45.1 ± 0.54.2–6.27.8 ± 1.25.5–10.5
2-h glucose after 75-g OGTT (mmol/L)5.4 ± 1.24.4–7.16.3 ± 1.52.8–8.5NANA
HbA1c (%)5.3 ± 0.15.1–5.55.4 ± 0.34.8–5.97.2 ± 0.56.3–8.4
Duration of diabetes (years)NANA6 ± 60–24
Pretreatment with metformin, nNANA
 Yes22
 No10
 % yes68.8
Metformin dose (mg/day)NANA1,581 ± 548
Triglycerides (mmol/L)1.3 ± 0.60.5–3.11.9 ± 0.90.6–4.4
Serum creatinine (μmol/l)80 ± 1862–9785 ± 1067–11683 ± 1261–105
  • Data are mean ± SD or range unless otherwise indicated. NA, not applicable; OGTT, oral glucose tolerance test.